TrialJournal of neurodevelopmental disorders2026

Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031).

Helen Heussler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.